SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Enliven Therapeutics, Inc. (ELVN) News

Follow Enliven Therapeutics, Inc. (ELVN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 8 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol ELVN Asset equity Sector Markets 90 days 4 Last 46.53 Updated Nov 05, 2026, 10:06 PM UTC Open live news feed Open ELVN chart & news
M Enliven Therapeutics Q3 Net Loss Widens on Higher R&D Spending EQUITY | Nov 05, 2026, 10:06 PM UTC M Enliven Therapeutics Reports Third-Quarter 2026 Financial Results Enliven Therapeutics said it aligned with the FDA on the final design of its ENABLE-2 pivotal Phase 3 trial and remains on track to start it before year-end. The company reported $884 million in cash, cash equivalents an EQUITY | Nov 05, 2026, 09:07 PM UTC L ELVN - Enliven Therapeutics to Present at Upcoming Investor Conferences ELVN - Enliven Therapeutics to Present at Upcoming Investor Conferences EQUITY | Sep 03, 2026, 08:06 PM UTC L Enliven Therapeutics to present at SOHO 2026 annual meeting Enliven Therapeutics (ELVN) announced oral and poster presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting. EQUITY | Aug 31, 2026, 10:06 PM UTC L ELVN ELVN - Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update ELVN ELVN - Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update EARNINGS | Aug 05, 2026, 08:06 PM UTC L Enliven Therapeutics Insider Sold Shares Worth $504,903, According to a Recent SEC Filing () -- Lori Anne Kunkel, Director, on July 06, 2026, sold 10,000 shares in Enliven Therapeutics (ELVN) for $504,903. Following the Form 4 filing with the SEC, Kunkel has control over a total of 41,884 common shares of the REGULATION | Jul 08, 2026, 09:22 PM UTC L Stifel Maintains Buy on Enliven Therapeutics, Raises Price Target to $80 Stifel analyst Dara Azar maintains Enliven Therapeutics (NASDAQ: ELVN ) with a Buy and raises the price target from $60 to $80. EQUITY | Jul 01, 2026, 02:02 PM UTC M Jones Trading Maintains Buy on Enliven Therapeutics, Raises Price Target to $70 Jones Trading analyst Boris Peaker maintains Enliven Therapeutics (NASDAQ: ELVN ) with a Buy and raises the price target from $45 to $70. EQUITY | Jun 29, 2026, 03:34 PM UTC